
    
      To provide the Centers for Biologic Evaluation and Research (CBER) with sera collected from
      healthy children receiving the 2004-2005 formulation of the inactivated, split-virion
      influenza vaccine FluzoneÂ® for further study by the Food and Drug Administration (FDA),
      Centers for Disease Control and Prevention (CDC), and the World Health Organization (WHO).
    
  